We describe the downstream effects on protein expression of recurrent molecular features of CLL and use the unique case-control design of our early-stage cohort to identify THEMIS2 as novel, independent biomarker associated with TTFT at the time of sampling. Here, THEMIS2 is linked to B-cell chronic lymphocytic leukemia.